← Back to Search

Hormone Therapy

Megestrol + Metformin for Endometrial Cancer Prevention

Phase 2
Recruiting
Led By Emma Barber
Research Sponsored by National Cancer Institute (NCI)
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Patients on chronic suppressive antiviral therapy for herpes simplex virus (HSV) are eligible
Must be a candidate and accepting of surgical management of EIN with planned hysterectomy
Must not have
Women who are diabetics taking sulfonylureas and meglitinides will be excluded
Pregnant women are excluded from this study because it requires hysterectomy which is contraindicated in women who are pregnant and wish to continue the pregnancy. Additionally, megestrol acetate is a category D agent. Megestrol acetate may cause fetal harm when administered to a pregnant woman
Timeline
Screening 3 weeks
Treatment Varies
Follow Up up to 42 days post planned procedure
Awards & highlights

Summary

This trial is testing whether a combination of two drugs, megestrol acetate and metformin, is more effective than megestrol acetate alone in preventing the progression of uterine pre-cancer (endometrial intraepithelial neoplasia) to endometrial cancer.

Who is the study for?
This trial is for adults with a pre-cancerous condition of the uterus called endometrial intraepithelial neoplasia (EIN), who are planning to have a hysterectomy. They must be in good health, not pregnant, and willing to use birth control if they can have children. People with certain viral infections must be on treatment with an undetectable viral load.
What is being tested?
The study is testing whether taking megestrol acetate alone or combined with metformin prevents EIN from turning into uterine cancer better than just megestrol acetate. Participants will receive these medications before their planned surgery to remove the uterus.
What are the potential side effects?
Megestrol may cause weight gain, increased blood pressure, and blood clots. Metformin can lead to stomach issues like diarrhea and nausea, as well as a rare but serious condition called lactic acidosis especially in people who drink alcohol excessively.

Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below
Select...
I am on long-term antiviral treatment for herpes.
Select...
I am willing to undergo a hysterectomy for my endometrial condition.
Select...
I had hepatitis C but am cured, or I'm being treated with no detectable virus.
Select...
I am 18 years old or older.
Select...
My hepatitis B virus load is undetectable with treatment.
Select...
I can take care of myself but might not be able to do heavy physical work.

Exclusion Criteria

You may be eligible for the trial if you check “No” for criteria below:
Select...
I am not a diabetic woman taking sulfonylureas or meglitinides.
Select...
I am not pregnant as the study requires surgery and medication that could harm a fetus.
Select...
I am not breastfeeding as it may harm my nursing infant due to my treatment.
Select...
I am a woman with a history of alcohol use disorder.
Select...
I am not taking dofetilide, ulipristal, carbonic anhydrase inhibitors, ranolazine, vandetanib, dolutegravir, or cimetidine.
Select...
I have had a blood clot in my lungs, brain, arteries, or deep veins.
Select...
My cancer is active again.

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~baseline up to 42 days post planned procedure
This trial's timeline: 3 weeks for screening, Varies for treatment, and baseline up to 42 days post planned procedure for reporting.

Treatment Details

Study Objectives

Study objectives can provide a clearer picture of what you can expect from a treatment.
Primary study objectives
Percentage of Ki-67 positive cells
Secondary study objectives
Changes in protein expression
Other study objectives
Ki-67 expression

Trial Design

2Treatment groups
Experimental Treatment
Active Control
Group I: Arm II (megestrol acetate, metformin hydrochloride)Experimental Treatment4 Interventions
Prior to standard of care planned procedure, patients receive megestrol acetate PO BID and metformin hydrochloride extended-release PO BID for 21-35 days (up to and including the night before planned procedure) in the absence of disease progression or unacceptable toxicity. Patients also undergo biopsy on the day of planned procedure.
Group II: Arm I (megestrol acetate)Active Control3 Interventions
Prior to standard of care planned procedure, patients receive megestrol acetate PO BID for 21-35 days (up to and including the night before planned procedure) in the absence of disease progression or unacceptable toxicity. Patients also undergo biopsy on the day of planned procedure.
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
Biopsy
2014
Completed Phase 4
~1090
Megestrol Acetate
2007
Completed Phase 3
~540

Find a Location

Who is running the clinical trial?

National Cancer Institute (NCI)Lead Sponsor
13,842 Previous Clinical Trials
41,002,950 Total Patients Enrolled
75 Trials studying Endometrial Cancer
73,304 Patients Enrolled for Endometrial Cancer
Emma BarberPrincipal InvestigatorNorthwestern University

Media Library

Megestrol Acetate (Hormone Therapy) Clinical Trial Eligibility Overview. Trial Name: NCT04576104 — Phase 2
Endometrial Cancer Research Study Groups: Arm I (megestrol acetate), Arm II (megestrol acetate, metformin hydrochloride)
Endometrial Cancer Clinical Trial 2023: Megestrol Acetate Highlights & Side Effects. Trial Name: NCT04576104 — Phase 2
Megestrol Acetate (Hormone Therapy) 2023 Treatment Timeline for Medical Study. Trial Name: NCT04576104 — Phase 2
~3 spots leftby Nov 2024
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top